| Literature DB >> 27999749 |
Limo Chen1, Xiaohui Yi2, Sangeeta Goswami1, Young-Ho Ahn3, Jonathon D Roybal1, Yongbin Yang4, Lixia Diao5, Di Peng6, David Peng1, Jared J Fradette1, Jing Wang5, Lauren A Byers1, Jonathan M Kurie1, Stephen E Ullrich2, F Xiao-Feng Qin7, Don L Gibbons8.
Abstract
Cancer cells modulate the recruitment and function of inflammatory cells to create an immunosuppressive microenvironment that favors tumor growth and metastasis. However, the tumor-derived regulatory programs that promote intratumoral immunosuppression remain poorly defined. Here, we show in a KrasLA1/+p53R172HΔg/+-based mouse model that bone morphogenetic protein-4 (BMP4) augments the expression of the T cell co-inhibitory receptor ligand PD-L1 in the mesenchymal subset of lung cancer cells, leading to profound CD8+ T cell-mediated immunosuppression, producing tumor growth and metastasis. We previously reported in this model that BMP4 functions as a pro-tumorigenic factor regulated by miR-200 via GATA4/6. Thus, BMP4-mediated immunosuppression is part of a larger miR-200-directed gene expression program in tumors that promotes tumor progression, which could have important implications for cancer treatment.Entities:
Keywords: BMP4; EMT; PD-L1; immunotherapy; lung cancer; miR-200
Year: 2016 PMID: 27999749 PMCID: PMC5139626 DOI: 10.1080/2162402X.2016.1234570
Source DB: PubMed Journal: Oncoimmunology ISSN: 2162-4011 Impact factor: 8.110